Samlyn Capital, LLC Nurix Therapeutics, Inc. Transaction History
Samlyn Capital, LLC
- $6.21 Billion
- Q4 2024
A detailed history of Samlyn Capital, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 515,840 shares of NRIX stock, worth $7.01 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
515,840
Previous 568,264
9.23%
Holding current value
$7.01 Million
Previous $12.8 Million
23.82%
% of portfolio
0.16%
Previous 0.21%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$92.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$59.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$57 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$52.8 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$48.7 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $641M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...